Exercise on GLP-1.

Most articles about GLP-1 medications and exercise either skip the topic or pivot to a branded workout program with a celebrity trainer. This article does neither. The medication is doing one job: appetite suppression, slowed gastric emptying, sustained energy deficit, and real cardiovascular benefit. It is not doing the job of preserving the muscle you lose along with the fat.

The numbers are not subtle. Across clinical trials and case series, between 26 and 40% of weight lost on a GLP-1 is lean mass rather than fat. Not all of that is contractile muscle, but enough of it is to matter functionally: slower metabolism, weaker grip, harder stairs, more fragility in older bodies. In 2025, four medical societies (ACLM, ASN, OMA, TOS) converged on a joint advisory that put protein intake and resistance training in the same sentence as the medication itself. Three legs of one stool. Pull any leg, and outcomes degrade.

What follows is a plain-language summary of what the expert consensus says and where the line sits between "guideline" and "talk to your provider."

Why the medication can't do this part for you.

The mechanism that makes a GLP-1 effective for fat loss is the same mechanism that puts lean mass at risk. Rapid weight loss in any context (caloric restriction, bariatric surgery, GLP-1 therapy) loses both fat and muscle. The drug controls the energy deficit. It does not control the composition of what gets lost.

The STEP 1 body-composition substudy quantified this with semaglutide 2.4 mg over 68 weeks: total lean mass fell 9.7%, fat mass fell 19.3%. Lean as a proportion of total body mass rose 3 points because fat fell faster, but lean mass still fell.

The medication is doing the fat-loss work. The medication is not doing the muscle-preservation work. That part is yours.

The SEMALEAN study (2026) is the most useful real-world data point. In 115 patients on semaglutide 2.4 mg with DXA scans at baseline, 7 months, and 12 months, lean mass fell about 3 kg by month 7 and then stabilized. Handgrip strength improved by 4.5 kg at month 12, and sarcopenic obesity prevalence fell from 49% to 33%. Participants received nutrition and physical-activity counseling alongside the medication. Function improved even as lean mass dropped, because the muscle that survived was doing more work.

An adjacent piece of evidence sets the magnitude of what is biologically possible. The BELIEVE Phase 2b trial (ADA 2025) combined semaglutide with bimagrumab, an investigational antibody. The combination delivered about 22% weight loss at 72 weeks with roughly 92% of the loss from fat; the semaglutide-alone arm delivered about 72% fat-only loss. Bimagrumab is not approved; this is not a recommendation, only an illustration. The gap between "medication alone" and "medication plus muscle-preservation intervention" is large enough to matter clinically. The behavioral analogue of that gap is protein plus resistance training.

A safety note: if you have a history of heart disease, recent cardiac events, severe joint disease, or you are on a sulfonylurea or insulin alongside your GLP-1, talk to your provider before starting a new exercise routine. Your prescriber may want to adjust other glucose-lowering drugs before you add training volume.

What the consensus actually says.

Two documents do most of the work here, plus a global floor from WHO. They agree more than they disagree, and they disagree mostly on dose.

The Joint Advisory from ACLM, ASN, OMA, and TOS (American Journal of Clinical Nutrition, 2025) is the GLP-1-specific document. On exercise, it points to intentional physical activity 4 to 7 days per week, with resistance training on 3 to 5 of those days, alongside a protein-intake range. It does not specify intensity, load, or specific exercises. That is deliberate. Individualization belongs to the clinician and trainer.

The ACSM 2024 obesity consensus was the first comprehensive update in 15 years to physical activity and weight-management guidance, and the first such consensus to explicitly address weight-loss medications. Its 2026 resistance training guideline update drew on 137 systematic reviews and emphasizes a difficult fact: about 60% of US adults do no muscle-strengthening exercise at all. That is the baseline most new GLP-1 users start from.

The WHO floor is at least 150 minutes of moderate-intensity aerobic activity per week, plus muscle-strengthening activities on 2 or more days a week. WHO is the floor. The Joint Advisory is the GLP-1-adjusted target. Both are guidelines, not prescriptions.

The Joint Advisory's 3-to-5-days resistance training is the upper-bound of a guideline range for a population on a powerful weight-loss medication. It is not a directive that says you must lift five days a week or fail. Many people will start at the WHO floor (2 days per week) and progress under guidance. That is appropriate.

The Joint Advisory recommends 3 to 5 days of resistance training per week. It does not recommend a workout. The workout is a conversation between you, a trainer, and your provider.

Resistance training, in plain language.

Resistance training is any activity where you ask your muscles to work against load. The load can be your own body weight, a resistance band, dumbbells, a kettlebell, or a machine at a gym. The mode matters less than the principle: the body adapts to demand, and demand has to keep increasing, slowly, for adaptation to continue. That principle is called progressive overload, and it works the same whether you are 30 or 70.

Most expert-society guidance describes resistance training in terms of movement patterns rather than specific exercises. Four patterns cover the major muscle groups: an upper-body push, an upper-body pull, a lower-body squat or hinge, and a core or carry. Bodyweight, band, dumbbell, and machine versions exist for all four. A physical therapist or credentialed trainer can match the right version to your starting point, equipment, and joints.

A 2025 systematic review summarizes the evidence. Resistance exercise during dietary weight loss did not change total weight loss, but it produced greater fat loss, preserved fat-free mass, and increased strength. Aerobic exercise alone during a caloric deficit was associated with 2 to 3 kg of lean-mass loss; adding resistance training was associated with roughly 0.8 kg of lean-mass gain. A 2025 Frontiers in Endocrinology review found 85% of participants in resistance training arms gained lean body mass during weight loss, against 50% of aerobic-only participants who lost it.

Two pieces of plain advice. First, form before load. Adults new to lifting do not need to lift heavy; they need to lift correctly, often enough that the body adapts. A trainer-supervised first month or physical-therapy referral is the standard on-ramp. Second, recovery is part of the prescription. Adaptation happens between sessions, not during them.

Walking.

Walking is the most accessible modality and the one most GLP-1 users will actually do. What it does well: improves cardiovascular health, mood, glycemic control, and joint mobility. Step counts up to 10,000 per day are associated with lower risk of cardiovascular disease, heart failure, stroke, dementia, and type 2 diabetes.

What walking does not do: by itself, it does not preserve muscle during a weight-loss energy deficit. Intensity matters too; body-composition benefits in trials required moderate-intensity walking (above roughly 103 steps per minute), not just hitting a step count slowly.

Walking is excellent for your heart, your mood, and your blood sugar. It is not a substitute for resistance training when the goal is muscle preservation.

Combined, not either-or.

The Joint Advisory's "4 to 7 days of activity, 3 to 5 days of resistance training" is essentially a description of concurrent training. Aerobic does what resistance does not (cardiorespiratory fitness, glycemic control, mood). Resistance does what aerobic does not (muscle preservation, strength, bone density). The combination outperforms either alone on body composition during a caloric deficit.

The SELECT trial showed a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight or obesity and established CV disease, largely independent of weight-loss magnitude. The medication is doing direct CV work; exercise adds on top. For anyone with cardiac history, a supervised cardiac rehabilitation program is the standard on-ramp.

Timing, fuel, and recovery on a low-appetite drug.

The operational guidance for training on GLP-1 is short, and most of it is about fueling around training. Muscle protein synthesis rises for several hours after a protein-rich meal and peaks around 2 hours after intake. The consensus dose range is roughly 20 to 40 grams of high-quality protein per eating occasion, with older adults often needing the higher end because of anabolic resistance. On a drug that suppresses appetite, hitting that threshold around training can be the hardest part. Greek yogurt, cottage cheese, a shake, or a small portion of leftover protein are common solutions; liquid options are often better tolerated on training days.

Thirst signaling is reduced on GLP-1. Plan electrolyte-containing fluids around training. Do not rely on thirst to tell you when to drink.

Fasted high-intensity training on a GLP-1 is a bad combination. The medication is already producing an energy deficit, and training fasted compounds it. If a session is planned, eat something protein-anchored beforehand. If side effects make eating impossible, reschedule. A missed workout is recoverable. An injury from training on empty is not. Sleep is part of recovery too; adaptation degrades on short sleep.

What not to do.

• Do not substitute exercise for medication. Stopping a GLP-1 in favor of "just exercise" is associated with significant weight regain, because the underlying biology has not changed.
• Do not train fasted at high intensity on a drug that suppresses appetite and slows gastric emptying.
• Do not ignore new pain that does not match what you did, particularly chest pain, severe shortness of breath, or joint pain that worsens with use.
• Do not compound a caloric deficit with an overtraining schedule. Recovery is part of the dose.
• Do not push through nausea on a training day. Reschedule.
• Do not take advice from fitness influencers as primary medical guidance. Trainers help with form; physicians and registered dietitians help with safety on medication.

Special populations.

Older adults.

Sarcopenic obesity affects roughly 28% of people over 60 with obesity. Anabolic resistance raises the per-meal protein threshold to roughly 30 to 40 grams, and it raises the case for resistance training. Older adults are also more likely to be on a sulfonylurea or insulin in addition to a GLP-1; talk to your prescriber about dose adjustments before adding regular exercise.

People with joint pain or osteoarthritis.

A propensity-matched cohort found tirzepatide users had lower musculoskeletal pain (especially knee) and reduced high-risk analgesic use compared with matched patients on phentermine, driven largely by weight loss. Note that Zepbound is FDA-approved for chronic weight management (Nov 2023) and for moderate-to-severe obstructive sleep apnea (Dec 2024); it is not approved for osteoarthritis. For people with OA whose weight is coming down, a window may open for movement that was painful before. Low-impact resistance work (machines, bands, pool, chair-based circuits) is the standard accommodation. A physical therapist is the right starting point.

Cardiac patients.

Anyone with recent myocardial infarction, unstable angina, or heart failure should not start a new resistance training routine without provider clearance. Cardiac rehabilitation programs offer graded exercise testing and supervised, individualized programming, and the SELECT cardiovascular benefit shown in this population was alongside (not instead of) recommendations to maintain physical activity.

Post-bariatric users.

The bariatric literature generalizes well to GLP-1. Resistance training after bariatric surgery does not change total weight loss but preserves lean mass, reduces waist circumference, and increases fat loss. GLP-1 users can borrow the same principles: form first, progress slowly, get supervised onboarding.

Red flags for clinical attention.

GLP-1 receptor agonists alone are low risk for hypoglycemia because their insulin-stimulating effect is glucose-dependent. The combination with sulfonylureas or insulin is different. Pharmacovigilance data and the Joint Advisory both flag this combination as one where exercise volume changes should be coordinated with your prescriber, not added unilaterally.

How this fits with what you are already tracking.

The scale alone is a poor proxy for what resistance training is buying you on a GLP-1, exactly because of the SEMALEAN finding: lean mass can fall and stabilize while function improves. If you only watch one number, you will misread the picture during a weight plateau and as you approach maintenance.

What helps is keeping a log with more than one signal: body measurements (waist especially), repeatable strength markers (sit-to-stand count, carry distance), energy levels, and weight as one of several inputs. Strength gains are real, even when the scale is flat. A registered dietitian can help set protein-around-training targets that fit your appetite on this medication.

Up to 40% of weight lost on a GLP-1 can be lean mass. Resistance training is the variable that changes that number.

The three-legged stool is the framing worth keeping. Medication is one leg. Protein is the second leg. Resistance training is the third leg. The medication reduces appetite, slows gastric emptying, and protects the cardiovascular system in ways exercise alone cannot. Protein and training protect the muscle that the medication does not. Pull any leg, and outcomes degrade.

This article is for educational purposes only and is not medical advice. It is not an exercise prescription. Talk to your provider before starting a new exercise routine, especially if you have a history of cardiac disease, recent cardiac events, severe joint disease, or you are on a sulfonylurea or insulin alongside your GLP-1. A credentialed trainer or physical therapist is the appropriate professional for movement onboarding. Read our editorial process to see how this article was sourced and reviewed.